WO2003092591A3 - Multi-phasic delivery via transmucosal absorption of antiemetic medicaments - Google Patents

Multi-phasic delivery via transmucosal absorption of antiemetic medicaments Download PDF

Info

Publication number
WO2003092591A3
WO2003092591A3 PCT/US2003/013255 US0313255W WO03092591A3 WO 2003092591 A3 WO2003092591 A3 WO 2003092591A3 US 0313255 W US0313255 W US 0313255W WO 03092591 A3 WO03092591 A3 WO 03092591A3
Authority
WO
WIPO (PCT)
Prior art keywords
antiemetic
transmucosal absorption
active
delivery via
phasic
Prior art date
Application number
PCT/US2003/013255
Other languages
French (fr)
Other versions
WO2003092591A2 (en
Inventor
John M Pinney
Edward J Cone
Original Assignee
Npd Llc
John M Pinney
Edward J Cone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Npd Llc, John M Pinney, Edward J Cone filed Critical Npd Llc
Priority to AU2003241322A priority Critical patent/AU2003241322A1/en
Publication of WO2003092591A2 publication Critical patent/WO2003092591A2/en
Publication of WO2003092591A3 publication Critical patent/WO2003092591A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention concerns a composition for oral administration of an active for suppressing nausea and vomiting. The composition comprises a carrier, an antiemetic active, and a buffer. The carrier may be a gum, a lozenge, a candy or a tablet suitable for administration in an oral cavity. The buffer is water-soluble, and facilitates bi-phasic release of the active for transmucosal absorption. The method of delivering the antiemetic active in a bi-phasic manner is also provided.
PCT/US2003/013255 2002-04-30 2003-04-30 Multi-phasic delivery via transmucosal absorption of antiemetic medicaments WO2003092591A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003241322A AU2003241322A1 (en) 2002-04-30 2003-04-30 Multi-phasic delivery via transmucosal absorption of antiemetic medicaments

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37626302P 2002-04-30 2002-04-30
US60/376,263 2002-04-30

Publications (2)

Publication Number Publication Date
WO2003092591A2 WO2003092591A2 (en) 2003-11-13
WO2003092591A3 true WO2003092591A3 (en) 2004-03-25

Family

ID=29401323

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/013255 WO2003092591A2 (en) 2002-04-30 2003-04-30 Multi-phasic delivery via transmucosal absorption of antiemetic medicaments

Country Status (2)

Country Link
AU (1) AU2003241322A1 (en)
WO (1) WO2003092591A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
JP5179757B2 (en) * 2004-02-17 2013-04-10 トランセプト ファーマシューティカルズ， インコーポレイティド Composition for delivering a hypnotic agent through the oral mucosa and method of use thereof
US8642016B2 (en) 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
US20080187589A1 (en) * 2007-02-05 2008-08-07 Pinney John M Multi-modal delivery via transmucosal and gastro-intestinal absorption of antihistamines and symptom relief
US9855227B2 (en) * 2015-12-18 2018-01-02 The Procter & Gamble Company Quick dissolving diphenhydramine oral dosage form

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310561A (en) * 1990-09-10 1994-05-10 Alza Corporation Antiemetic therapy
US5866157A (en) * 1994-11-29 1999-02-02 Hisamitsu Pharmaceutical Co., Ltd. Matrix patch formulation
US6197329B1 (en) * 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
US6316027B1 (en) * 1995-08-18 2001-11-13 R. P. Scherer Technologies, Inc. Fast-dissolving dosage forms for dopamine agonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310561A (en) * 1990-09-10 1994-05-10 Alza Corporation Antiemetic therapy
US5866157A (en) * 1994-11-29 1999-02-02 Hisamitsu Pharmaceutical Co., Ltd. Matrix patch formulation
US6316027B1 (en) * 1995-08-18 2001-11-13 R. P. Scherer Technologies, Inc. Fast-dissolving dosage forms for dopamine agonists
US6197329B1 (en) * 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods

Also Published As

Publication number Publication date
AU2003241322A1 (en) 2003-11-17
AU2003241322A8 (en) 2003-11-17
WO2003092591A2 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
CA2365826A1 (en) Over-coated chewing gum formulations
CA2426349A1 (en) Over-coated chewing gum formulations including tableted center
WO2003066029A3 (en) Pharmaceutical dosage form for mucosal delivery
LU92636I2 (en) Zolpidem and its pharmaceutically acceptable salts
YU33099A (en) Pharmaceutical composition
AU1232600A (en) Dosage forms containing taste masked active agents
EP1987821A3 (en) Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
CA2333375A1 (en) Sublingual buccal effervescent
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
CA2274910A1 (en) Flat medicament preparation for the application and release of buprenorphine or a pharmacologically comparable substance in the buccal cavity, and method of producing the same
HK1040614A1 (en) Nicotine-containing pharmaceutical compositions giving a rapid transmucosal absorption
HK1081844A1 (en) Compositions for transmucosal drug delivery and cryoprotection
AU1079701A (en) Oral transmucosal drug dosage using solid solution
GB9908014D0 (en) Pharmaceutical compositions
HK1044715A1 (en) Pregelatinized starch in a controlled release formulation
CA2099670A1 (en) Flavor stable zinc acetate compositions for oral absorption
GB0320854D0 (en) Buccal drug delivery
SE0102276D0 (en) Device and method for administering a drug
WO2004032866A3 (en) Therapeutic formulations
WO2002024203A3 (en) Controlled release formulations for oral administration
WO2000013662A3 (en) Medicated chewing gum delivery system for nicotine
ES2130081A1 (en) Coated trimebutine maleate tablet
AU2003246567A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
AU2003238644A1 (en) Stable compositions of water sensitive ingredients
WO2006100595A3 (en) Chewing gum compositions of varenicline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP